


Alpelisib

Chemical Properties

CAS No. :	1217486-61-7
Formula:	C ₁₉ H ₂₂ F ₃ N ₅ O ₂ S
Molecular Weight:	441.47
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Alpelisib (BYL-719) is a PI3K α inhibitor (IC ₅₀ =5 nM) with selective, potent, and oral activity, inhibiting PI3K β / γ / δ with low activity (IC ₅₀ =250/290/1200 nM). Alpelisib demonstrates antitumor activity and specifically targets PIK3CA mutant tumors.
Targets(IC ₅₀)	PI3K
In vitro	<p>METHODS: Osteosarcoma cell lines MG-63, HOS, MOS-J and POS-1 were treated with Alpelisib (0-50 μM) for 72 h and cell viability was measured using XTT assay.</p> <p>RESULTS: Alpelisib significantly inhibited cell growth of all osteosarcoma cell lines in a dose-dependent manner with IC₅₀ ranging from 6-15 μM and IC₉₀ ranging from 24-42 μM. [1]</p> <p>METHODS: PIK3CA wild-type cells (SNU638 and SNU668) and three PIK3CA mutant cells (SNU601, AGS, and MKN1) were treated with Alpelisib (5 μM) for 24 h, and cell cycle profiles were examined using Flow cytometry.</p> <p>RESULTS: Alpelisib treatment induced G₀/G₁ cell cycle arrest regardless of PIK3CA mutation status. In PIK3CA mutant cells (AGS and MKN1), there was a significant increase in the sub-G₁ fraction, suggesting that Alpelisib increased apoptosis in these cell lines. [2]</p>
In vivo	<p>METHODS: To assay anti-tumor activity in vivo, Alpelisib (12.5-50 mg/kg, methylcellulose 0.5%) was administered orally to Rj:NMRI-nude mice bearing human osteosarcoma HOS-MNNG once daily for twenty-two days.</p> <p>RESULTS: Alpelisib significantly reduced tumor volume in a dose-dependent manner. [1]</p> <p>METHODS: To investigate the modulatory effects on collagen, Alpelisib (12.5-50 mg/kg) was administered orally to nude mice bearing subcutaneous xenografts of Rat1-myr-p110α tumors once daily for eight days.</p> <p>RESULTS: Treatment with 12.5, 25, and 50 mg/kg of Alpelisib was well tolerated and produced dose-dependent and statistically significant antitumor effects with a T/C of 14.1% and regressions of 9.6% and 65.2%, respectively. [3]</p>
Cell Research	To evaluate the isoform-specific potency of NVP-BYL719 in a cell-based system, an N-terminally myristoylated form of each PI3K class IA isoform was expressed in Rat1 fibroblasts. The retroviral expression plasmid pBabePuro containing human p110 α , p110 β , and p110 δ with an N-terminal myristoylation (myr) signal followed by an HA-tag were generated. Successfully infected Rat1 cells were selected in medium containing 4 μ g/mL of puromycin, expanded and characterized for expression of the p110 isoforms.

A DRUG SCREENING EXPERT

Cell Research	Transgenic expression of the myristoylated protein was confirmed by increased levels of phosphorylated Akt [1].
Animal Research	All in life experimentation and efficacy studies were conducted as described previously. Tumor xenografts were grown subcutaneously or orthotopically in nude mice or nude Rowett rats (Hsd: RH-Fox1rnu) by injection of 3×10^6 to 1×10^7 cells or implantation of tumor fragments of approximately 50 mg. Tumor-bearing animals mice were treated with either vehicle control, NVP-BYL719, or NVP-BKM120 (p.o., every day) at the doses indicated [1].

Solubility Information

Solubility	DMSO: 240 mg/mL (543.64 mM),Sonication is recommended. Ethanol: 2 mg/mL (4.53 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.2 mg/mL (18.57 mM),Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2652 mL	11.3258 mL	22.6516 mL
5 mM	0.453 mL	2.2652 mL	4.5303 mL
10 mM	0.2265 mL	1.1326 mL	2.2652 mL
50 mM	0.0453 mL	0.2265 mL	0.453 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Gobin B, et al. BYL719, a new α -specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. *Int J Cancer*. 2015 Feb 15;136(4):784-96.
- Liao W, Wang Z, Han Y, et al. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3K α inhibitors with potent antitumor activity. *European Journal of Medicinal Chemistry*. 2020, 197: 112309
- Kim KJ, et al. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. *Sci Rep*. 2020 Jul 23;10(1):12308.
- Yang T, Xu R, Su Q, et al. Chelerythrine hydrochloride inhibits proliferation and induces mitochondrial apoptosis in cervical cancer cells via PI3K/BAD signaling pathway. *Toxicology in Vitro*. 2020, 68: 104965.
- Fritsch C, et al. Characterization of the novel and specific PI3K α inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. *Mol Cancer Ther*. 2014 May;13(5):1117-29.
- Chen R, Wang Z, Sima L, et al. Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K α inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*. 2023, 38(1): 2155638.
- Elkabets M, et al. mTORC1 inhibition is required for sensitivity to PI3K p110 α inhibitors in PIK3CA-mutant breast cancer. *Sci Transl Med*. 2013 Jul 31;5(196):196ra99.
- Sugawara T, Nevedomskaya E, Heller S, et al. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. *Molecular Oncology*. 2024
- Yang T, Xu R, Su Q, et al. Chelerythrine hydrochloride inhibits proliferation and induces mitochondrial apoptosis in cervical cancer cells via PI3K/BAD signaling pathway[J]. *Toxicology in Vitro*. 2020, 68: 104965.
- Shi H, Pan B, Liang J, et al. miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. *Thoracic Cancer*. 2024
- Liao W, Wang Z, Han Y, et al. Design, synthesis and biological activity of novel 2, 3, 4, 5-tetra-substituted thiophene derivatives as PI3K α inhibitors with potent antitumor activity[J]. *European Journal of Medicinal Chemistry*. 2020: 112309.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481